Literature DB >> 15122713

Developmental effects of von Hippel-Lindau gene deficiency.

Alexander O Vortmeyer1, Quingyang Yuan, Youn-Soo Lee, Zhengping Zhuang, Edward H Oldfield.   

Abstract

The histogenetic origin and the basis of the distribution of central nervous system (CNS) hemangioblastomas in the von Hippel-Lindau (VHL) tumor suppressor gene syndrome, VHL disease, are unknown. To better understand hemangioblastoma histogenesis, we analyzed postmortem CNS tissues from four patients with well-established diagnosis of VHL disease including development of characteristic tumors and positive family history. Numerous angiomesenchymal tumorlets, which resembled hemangioblastoma, but which also consistently showed distinct histological features, were distributed in the nerve roots, spinal cord, and cerebellum. Genetic analysis consistently showed deletion of the wild-type VHL allele in these tumorlets. Most angiomesenchymal tumorlets were in the dorsal nerve roots; the anterior roots and cerebellum were less frequently affected. Tumorlet distribution was highly consistent in the four cases. In analogy to the wide morphological spectrum of lesions known to exist in VHL kidneys, nerve roots appear to harbor more wide-spread and morphologically heterogeneous changes than previously appreciated. The abundance of tumorlets, associated with highly consistent morphology and topography, suggests a developmental origin of hemangioblastoma. Therefore, in VHL disease, inactivation of the VHL wild-type allele appears necessary, but not sufficient, for the formation of tumor that produces symptoms and neurological disability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122713     DOI: 10.1002/ana.20090

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  VHL-deficient vasculogenesis in hemangioblastoma.

Authors:  Sven Gläsker; Jonathan Smith; Mark Raffeld; Jie Li; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Exp Mol Pathol       Date:  2014-01-04       Impact factor: 3.362

2.  Selection of surgical approach for cerebellar hemangioblastomas based on venous drainage patterns.

Authors:  Takashi Watanabe; Yuuki Suematsu; Kiyotaka Saito; Go Takeishi; Shinji Yamashita; Hajime Ohta; Kiyotaka Yokogami; Hideo Takeshima
Journal:  Neurosurg Rev       Date:  2021-04-20       Impact factor: 3.042

3.  Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Authors:  David Taïeb; Anne Barlier; Chunzhang Yang; Morgane Pertuit; Aurélie Tchoghandjian; Claire Rochette; Hélène Zattara-Canoni; Dominique Figarella-Branger; Zhengping Zhuang; Karel Pacak; Philippe Metellus
Journal:  J Neurooncol       Date:  2015-10-29       Impact factor: 4.130

Review 4.  Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Authors:  Chi-Chao Chan; Atif Ben Daniel Collins; Emily Y Chew
Journal:  Retina       Date:  2007-01       Impact factor: 4.256

5.  Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease.

Authors:  Chi-Chao Chan; Emily Y Chew; Defen Shen; Joseph Hackett; Zhengping Zhuang
Journal:  Mol Vis       Date:  2005-09-01       Impact factor: 2.367

6.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease.

Authors:  Gautam U Mehta; Sharon B Shively; Heng Duong; Maxine G B Tran; Travis J Moncrief; Jonathan H Smith; Jie Li; Nancy A Edwards; Russell R Lonser; Zhengping Zhuang; Marsha J Merrill; Mark Raffeld; Patrick H Maxwell; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

8.  A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect.

Authors:  Jing-Shan Huang; Chih-Ming Lin; Yu-Che Cheng; Kun-Long Hung; Chih-Cheng Chien; Shao-Kuan Chen; Chih-Ju Chang; Chan-Wei Chen; Chi-Jung Huang
Journal:  J Mol Med (Berl)       Date:  2009-03-14       Impact factor: 4.599

Review 9.  VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Authors:  W Kimryn Rathmell; Shufen Chen
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

10.  Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.

Authors:  Ian J Frew; Andrea Minola; Strahil Georgiev; Manuela Hitz; Holger Moch; Stéphane Richard; Alexander O Vortmeyer; Wilhelm Krek
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.